Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 8498501, Japan.
TARGET Investigator Group, Saga 8498501, Japan.
Int J Environ Res Public Health. 2023 Jan 19;20(3):1861. doi: 10.3390/ijerph20031861.
Obesity is associated with severe asthma, but no specific treatment has been established. The gut microbiome is increasingly recognized as a crucial factor, but specific treatments focused on the gut microbiome have not been established. Recently, azithromycin has been found to have the capacity to attenuate exacerbations, a characteristic of severe asthma. The effect of azithromycin on obesity-induced severe asthma is not understood.
The purpose of the present study is to clarify the effect of azithromycin on exacerbations in asthmatic patients with obesity. To explore the mechanism, the gut microbiome, metabolites of microbes such as short-chain fatty acids, and blood inflammatory cytokines will be analyzed to evaluate the correlation with the effect of azithromycin on exacerbations in obesity-induced severe asthma. A multi-center, prospective, single-arm intervention study is planned.
The present study will allow us to evaluate the effect of azithromycin on exacerbations, particularly in asthma patients with obesity, and explore biomarkers, targeting molecules including the gut microbiome, which are correlated with decreased exacerbations. The present results could contribute to identifying new therapeutic prospects and targeted microbes or molecules associated with severe clinical characteristics in asthmatic patients with obesity.
This study has been registered as a prospective study with the University Hospital Medical Information Network (UMIN0000484389) and the Japan Registry of Clinical Trials (jRCTs071220023).
肥胖与严重哮喘有关，但尚未确定具体的治疗方法。肠道微生物组越来越被认为是一个关键因素，但尚未确定针对肠道微生物组的具体治疗方法。最近，阿奇霉素被发现具有减轻恶化的能力，这是严重哮喘的一个特征。阿奇霉素对肥胖引起的严重哮喘的影响尚不清楚。
本研究旨在阐明阿奇霉素对肥胖型哮喘患者恶化的影响。为了探讨其机制，将分析肠道微生物组、微生物代谢物（如短链脂肪酸）和血液炎症细胞因子，以评估其与阿奇霉素对肥胖型严重哮喘恶化的疗效的相关性。计划进行一项多中心、前瞻性、单臂干预研究。
本研究将使我们能够评估阿奇霉素对恶化的影响，特别是在肥胖型哮喘患者中，并探索与恶化减少相关的生物标志物、靶向分子，包括肠道微生物组。本研究结果有助于确定肥胖型哮喘患者严重临床特征相关的新治疗前景和靶向微生物或分子。
本研究已作为一项前瞻性研究在大学医院医学信息网络（UMIN0000484389）和日本临床试验注册（jRCTs071220023）上注册。
